Blue Dye 2 vs Acesulfame Potassium: which is worse?

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.